These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 18076013)

  • 1. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
    Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
    Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
    Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
    Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
    Zlobec I; Baker K; Minoo P; Jass JR; Terracciano L; Lugli A
    Clin Cancer Res; 2008 Jan; 14(1):143-8. PubMed ID: 18172264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
    Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Bontenbal M; Jänicke F; Klijn JG
    Cancer Res; 1992 Nov; 52(21):6101-5. PubMed ID: 1394237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
    Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes.
    Zlobec I; Terracciano LM; Lugli A
    Clin Cancer Res; 2008 Jun; 14(12):3792-7. PubMed ID: 18559598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
    Karamitopoulou E; Zlobec I; Koumarianou A; Patsouris ES; Peros G; Lugli A
    Cancer; 2010 Oct; 116(19):4474-86. PubMed ID: 20572035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach.
    Tornillo L; Lugli A; Zlobec I; Willi N; Glatz K; Lehmann F; Spichtin HP; Maurer R; Stoios D; Sauter G; Terracciano L
    Am J Clin Pathol; 2007 Jan; 127(1):114-23. PubMed ID: 17145638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer.
    Zlobec I; Höller S; Tornillo L; Terracciano L; Lugli A
    Dis Colon Rectum; 2009 Jun; 52(6):1114-21. PubMed ID: 19581855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer.
    Seetoo DQ; Crowe PJ; Russell PJ; Yang JL
    J Surg Oncol; 2003 Mar; 82(3):184-93. PubMed ID: 12619063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
    Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
    Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.